CoChat

Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry

Phulphagar, Kshiti Meera, Ctortecka, Claudia, Jacome, Alvaro Sebastian Vaca, Klaeger, Susan, Verzani, Eva K., Hernandez, Gabrielle M., Udeshi, Namrata D., Clauser, Karl R., Abelin, Jennifer G., Carr, Steven A. · 2023 · Molecular & Cellular Proteomics

Published version of a preprint

Cited by 54

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mcpro.2023.100563

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 42

  1. Guedan, 2019, Emerging cellular therapies for cancer, Annu. Rev. Immunol., 37, 145, 10.1146/annurev-immunol-042718-041407 · DOI · Paper page
  2. Ouspenskaia, 2022, Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer, Nat. Biotechnol., 40, 209, 10.1038/s41587-021-01021-3 · DOI · Paper page
  3. Smart, 2018, Intron retention is a source of neoepitopes in cancer, Nat. Biotechnol., 36, 1056, 10.1038/nbt.4239 · DOI · Paper page
  4. Dendrou, 2018, HLA variation and disease, Nat. Rev. Immunol., 18, 325, 10.1038/nri.2017.143 · DOI · Paper page
  5. Taylor, 2021, MS-based HLA-II Peptidomics combined with multiomics will aid the development of future immunotherapies, Mol. Cell. Proteomics, 20, 10.1016/j.mcpro.2021.100116 · DOI
  6. Cattaneo, 2023, Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens, Nat. Biotechnol., 10.1038/s41587-022-01547-0 · DOI
  7. Friedman, 2012, Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes, J. Immunother., 35, 400, 10.1097/CJI.0b013e31825898c5 · DOI
  8. Kitano, 2013, Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients, Cancer Immunol. Res., 1, 235, 10.1158/2326-6066.CIR-13-0068 · DOI · Paper page
  9. Tran, 2014, Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer, Science, 344, 641, 10.1126/science.1251102 · DOI · Paper page
  10. Abelin, 2019, Defining HLA-II Ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction, Immunity, 51, 766, 10.1016/j.immuni.2019.08.012 · DOI · Paper page
  11. Hunt, 1992, Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry, Science, 255, 1261, 10.1126/science.1546328 · DOI · Paper page
  12. Stopfer, 2021, 1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs, Immunooncol. Technol., 11
  13. Becker, 2022, The importance of being presented: target validation by immunopeptidomics for epitope-specific immunotherapies, Front. Immunol., 13, 10.3389/fimmu.2022.883989 · DOI
  14. Shapiro, 2023, The impact of immunopeptidomics: from basic research to clinical implementation, Semin. Immunol., 66, 10.1016/j.smim.2023.101727 · DOI
  15. Chong, 2018, High-throughput and sensitive immunopeptidomics platform reveals profound interferonγ-mediated remodeling of the human leukocyte antigen (HLA) ligandome, Mol. Cell. Proteomics, 17, 533, 10.1074/mcp.TIR117.000383 · DOI · Paper page
  16. Klaeger, 2021, Optimized liquid and gas phase fractionation increases HLA-peptidome coverage for primary cell and tissue samples, Mol. Cell. Proteomics, 20, 10.1016/j.mcpro.2021.100133 · DOI
  17. Meier, 2021, Deep learning the collisional cross sections of the peptide universe from a million experimental values, Nat. Commun., 12, 1, 10.1038/s41467-021-21352-8 · DOI
  18. Casasola-LaMacchia, 2022, HLAII peptide presentation of infliximab increases when complexed with TNF, Front. Immunol., 13, 10.3389/fimmu.2022.932252 · DOI
  19. Nelde, 2022, Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity, iScience, 25, 10.1016/j.isci.2022.105643 · DOI
  20. Jaeger, 2022, Deciphering the immunopeptidome in vivo reveals new tumour antigens, Nature, 607, 149, 10.1038/s41586-022-04839-2 · DOI
  21. Abelin, 2023, Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues, Nat. Commun., 14, 1851, 10.1038/s41467-023-37547-0 · DOI
  22. Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity, 46, 315, 10.1016/j.immuni.2017.02.007 · DOI · Paper page
  23. Sarkizova, 2020, A large peptidome dataset improves HLA class I epitope prediction across most of the human population, Nat. Biotechnol., 38, 199, 10.1038/s41587-019-0322-9 · DOI · Paper page
  24. Kong, 2017, MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics, Nat. Methods, 14, 513, 10.1038/nmeth.4256 · DOI · Paper page
  25. Yu, 2020, Fast quantitative analysis of timsTOF PASEF data with MSFragger and IonQuant, Mol. Cell. Proteomics, 19, 1575, 10.1074/mcp.TIR120.002048 · DOI · Paper page
  26. Yu, 2021, IonQuant enables accurate and sensitive label-free quantification with FDR-controlled match-between-runs, Mol. Cell. Proteomics, 20, 10.1016/j.mcpro.2021.100077 · DOI · Paper page
  27. da Veiga Leprevost, 2020, Philosopher: a versatile toolkit for shotgun proteomics data analysis, Nat. Methods, 17, 869, 10.1038/s41592-020-0912-y · DOI · Paper page
  28. Kaczmarek, 2007, Analysis of expression of MHC class I molecules and TAP genes in malignant human cell lines, Folia Histochem. Cytobiol., 45, 205
  29. Mangalaparthi, 2021, Digging deeper into the immunopeptidome: characterization of post-translationally modified peptides presented by MHC I, J. Proteins Proteom., 12, 151, 10.1007/s42485-021-00066-x · DOI
  30. Ridgeway, 2018, Trapped ion mobility spectrometry: a short review, Int. J. Mass Spectrom., 425, 22, 10.1016/j.ijms.2018.01.006 · DOI · Paper page
  31. Fernandez-Lima, 2011, Gas-phase separation using a trapped ion mobility spectrometer, Int. J. Ion Mobil. Spectrom., 14, 10.1007/s12127-011-0067-8 · DOI · Paper page
  32. Almeida, 2009, CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens, Nucleic Acids Res., 37, D816, 10.1093/nar/gkn673 · DOI · Paper page
  33. Scanlan, 2002, Cancer/testis antigens: an expanding family of targets for cancer immunotherapy, Immunol. Rev., 188, 22, 10.1034/j.1600-065X.2002.18803.x · DOI · Paper page
  34. Erhard, 2020, Identification of the Cryptic HLA-I immunopeptidome, Cancer Immunol. Res., 8, 1018, 10.1158/2326-6066.CIR-19-0886 · DOI · Paper page
  35. Yewdell, 2022, MHC class I immunopeptidome: past, present, and future, Mol. Cell. Proteomics, 21, 10.1016/j.mcpro.2022.100230 · DOI
  36. Chong, 2020, Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes, Nat. Commun., 11, 1293, 10.1038/s41467-020-14968-9 · DOI · Paper page
  37. Ruiz Cuevas, 2021, Most non-canonical proteins uniquely populate the proteome or immunopeptidome, Cell Rep., 34, 10.1016/j.celrep.2021.108815 · DOI · Paper page
  38. Chen, 2022, PredMHC: an effective predictor of major histocompatibility complex using mixed features, Front. Genet., 13
  39. Jurtz, 2017, NetMHCpan-4.0: improved peptide-MHC class I interaction predictions Integrating eluted Ligand and peptide binding Affinity data, J. Immunol., 199, 3360, 10.4049/jimmunol.1700893 · DOI · Paper page
  40. Pak, 2021, Sensitive immunopeptidomics by leveraging available large-scale multi-HLA spectral Libraries, data-independent acquisition, and MS/MS prediction, Mol. Cell. Proteomics, 20, 10.1016/j.mcpro.2021.100080 · DOI
  41. Shahbazy, 2023, Benchmarking bioinformatics pipelines in data-independent acquisition mass spectrometry for immunopeptidomics, Mol. Cell. Proteomics, 22, 10.1016/j.mcpro.2023.100515 · DOI
  42. Xin, 2022, A streamlined platform for analyzing tera-scale DDA and DIA mass spectrometry data enables highly sensitive immunopeptidomics, Nat. Commun., 13, 3108, 10.1038/s41467-022-30867-7 · DOI

Cited by

Metadata

Authors
Phulphagar, K. M., Ctortecka, C., Jacome, A. S. V., Klaeger, S., Verzani, E. K., Hernandez, G. M., Udeshi, N. D., Clauser, K. R., Abelin, J. G., & Carr, S. A.
Venue
Molecular & Cellular Proteomics
Publisher
Elsevier BV
Published
2023-06
Volume
22
Issue
6
Pages
100563
ISSN
1535-9476
Cited by
54
References
13
Language
en
Licence
Funders
  • Swiss National Science Foundation (CRSII5_186405)
  • National Institutes of Health (P01CA206978)
  • National Cancer Institute (U01CA271402, U24CA270823)
  • Broad Institute
  • Doctor Miriam and Sheldon G Adelson Medical Research Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.